GRI Bio, Inc. Files 8-K on Security Holder Votes
Ticker: GRI · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1824293
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
GRI Bio (GRIB) shareholders voted on company matters Feb 11.
AI Summary
GRI Bio, Inc. filed an 8-K on February 11, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and governance, as required by the SEC.
Why It Matters
This filing indicates that GRI Bio, Inc. held a vote of its shareholders, which could pertain to significant corporate decisions such as board elections, mergers, or other strategic initiatives.
Risk Assessment
Risk Level: low — This is a routine filing to report on shareholder votes, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037 (address) — Principal executive offices
- Vallon Pharmaceuticals, Inc. (company) — Former company name
FAQ
What specific matters were submitted to a vote of GRI Bio, Inc.'s security holders on February 11, 2025?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals voted upon within the provided text.
What is the principal executive office address for GRI Bio, Inc.?
The principal executive offices are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
When did GRI Bio, Inc. change its name from Vallon Pharmaceuticals, Inc.?
The company formerly known as Vallon Pharmaceuticals, Inc. changed its name on September 10, 2020.
What is GRI Bio, Inc.'s telephone number?
GRI Bio, Inc.'s telephone number is (619) 400-1170.
What is the SIC code for GRI Bio, Inc.?
The Standard Industrial Classification (SIC) code for GRI Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2025-02-11 16:05:15
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20250211.htm (8-K) — 27KB
- val-20250211_g1.jpg (GRAPHIC) — 16KB
- val-20250211_g2.jpg (GRAPHIC) — 2KB
- 0001824293-25-000039.txt ( ) — 179KB
- val-20250211.xsd (EX-101.SCH) — 2KB
- val-20250211_lab.xml (EX-101.LAB) — 22KB
- val-20250211_pre.xml (EX-101.PRE) — 13KB
- val-20250211_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On February 11, 2025 at 9:00 a.m. Eastern Time, GRI Bio, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") virtually at www.virtualshareholdermeeting.com/GRI2025SM. Of the Company's 8,933,366 shares of common stock issued and outstanding and eligible to vote as of the record date of January 6, 2025 a quorum of 4,640,469 shares, or approximately 51.94% of the eligible shares, was present or represented by proxy. Each of the matters set forth below is described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on January 17, 2025. The following actions were taken at the Special Meeting: Proposal 1 The proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio within the range of not less than one-for-two and not more than one-for-twenty-three, with the exact ratio to be set within this range by the Company's board of directors (the "Board") in its sole discretion (without reducing the authorized number of shares of Company common stock) and with the Board able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by the Company's stockholders in its sole discretion, was approved by a majority of the votes cast by Company stockholders at the Special Meeting. Votes For Votes Against Votes Abstained Broker Non-Votes 3,151,775 1,484,078 4,616 — Proposal 2 The proposal to approve a postponement or adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1, was approved by a majority of the votes cast by Company stockholders at the Special Meeting. Votes For Votes Against Votes Abstained Broker Non-Votes 3,237,240 1,390,423 12,806 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 11, 2025 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer